Background: on 9 October 2026 the Union Health Ministry proposed a draft change that would tighten advertising rules for prescription medicines, as reported by Business Standard. It is a draft, and the final text may differ.
What was reported
Drugs listed under Schedules H, H1 and X of the Drugs Rules, 1945 already need prior Central Government approval before they are advertised. At present that requirement is described as applying to manufacturers. The draft would add a new sub-rule (22) to Rule 65 so that the restriction also covers entities licensed to sell, stock, display, offer for sale or distribute these drugs, including retail pharmacies and wholesale dealers.
The stated aims are better oversight across the supply chain, curbing unauthorised promotion of prescription medicines and reducing inappropriate self-medication. The draft follows a recommendation from the Drugs Technical Advisory Board in February 2026. Stakeholders can send objections and suggestions within 30 days of the Gazette copies being made available.
What this means for your clinic
If your clinic or hospital runs an in-house pharmacy, or promotes medicines, supplements or a dispensing service on its website, WhatsApp or social pages, do one check this week: list every page and post that names a prescription medicine, and confirm that none of them advertises it. Keep clinical education separate from anything that looks like promotion of a drug or a pharmacy offer. Re-check once the final notification is published.
This is a news summary, not legal or medical advice.
Sources: Business Standard, 9 Oct 2026.
